Plain-English translation of NCT05177133 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a small, early-stage study testing whether —a newer type of immune therapy—works well when combined with standard chemotherapy ( and ) for people with advanced stomach or esophageal cancer. Researchers will enroll 25 patients and carefully track how their tumors respond and how their immune system reacts to the treatment.
Stomach and esophageal cancers can be very difficult to treat, and many patients don't respond well to chemotherapy alone. This study explores whether adding the medication can help the body's own immune system fight the cancer more effectively.
You likely qualify if…
You likely don't qualify if…
You would receive two 3-week cycles of intravenous chemotherapy (the standard drugs and ), followed by regular injections of the new immune medication every four weeks for up to two years. Throughout the study, you'll have CT scans to monitor how your tumors are responding, and the research team will collect biopsies, blood samples, and stool samples to understand how your immune system is reacting.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Netherlands